Cleared Special

K152966 - Aequalis Fx2 (FDA 510(k) Clearance)

Jan 2016
Decision
99d
Days
Class 2
Risk

K152966 is an FDA 510(k) clearance for the Aequalis Fx2. This device is classified as a Shoulder Prosthesis, Reverse Configuration (Class II - Special Controls, product code PHX).

Submitted by Tornier S.A.S. (Montbonnot Saint Martin, FR). The FDA issued a Cleared decision on January 14, 2016, 99 days after receiving the submission on October 7, 2015.

This device falls under the Orthopedic FDA review panel. Regulated under 21 CFR 888.3660. Intended To Be Used To Relieve Pain And To Replace The Glenoid And Humeral Side Of The Shoulder Joint In Order To Restore Mobility In A Grossly Rotator Cuff Deficient Joint With Severe Arthropathy Or A Previous Joint Replacement With A Grossly Rotator Cuff Deficient Joint..

Submission Details

510(k) Number K152966 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 07, 2015
Decision Date January 14, 2016
Days to Decision 99 days
Submission Type Special
Review Panel Orthopedic (OR)
Summary Summary PDF

Device Classification

Product Code PHX — Shoulder Prosthesis, Reverse Configuration
Device Class Class II - Special Controls
CFR Regulation 21 CFR 888.3660
Definition Intended To Be Used To Relieve Pain And To Replace The Glenoid And Humeral Side Of The Shoulder Joint In Order To Restore Mobility In A Grossly Rotator Cuff Deficient Joint With Severe Arthropathy Or A Previous Joint Replacement With A Grossly Rotator Cuff Deficient Joint.

Similar Devices — PHX Shoulder Prosthesis, Reverse Configuration

All 39
INHANCE™ Reverse Shoulder System
K253624 · Depuy Ireland UC · Mar 2026
MSS - Monobloc stem
K250644 · Medacta International S.A. · Feb 2026
SMR Shoulder System
K252352 · Lima Corporate S.P.A. · Jan 2026
AltiVate Reverse® ADLC Glenosphere
K252567 · Encore Medical, L.P. · Jan 2026
Tornier Perform™ Reversed Monopost Glenoid (Perform Mono)
K252788 · Tornier, Inc. · Jan 2026
MSS - Humeral reverse liners extension
K250338 · Medacta International S.A. · Oct 2025